89 million dollars Income in 2025 36% YoY growth and 88% gross marginplural 159 million dollars Cash and 31 consecutive quarters of continuous growth – so far only ~3% penetration (647 of ~6,000 US hospitals), marking a significant increase.
Siri Bell has expanded its platform with infant/newborn cleaning algorithms and a baby head cap (initially planned Q2), received FDA approval for delirium November 2025 And lifted his TAM around 3.5 billion dollarsand secured FDA breakthrough designations for stroke January 2026.
The business model combines ~25% Subscription income (≈97% gross margin) and ~75% disposable caps, while the coverage of the investment area to the market has expanded from ~35 55 and received FedRAMP clearance to enable VA sales.
At CeriBell, Inc. Interested in? Here are five stocks we like best.
Cerebral (NASDAQ: CBLL ) is accelerating adoption of its point-of-care EEG platform in U.S. hospitals while expanding into new patient populations and indications, Chief Financial Officer Scott Blumberg said at the Raymond James Institute’s 47th Annual Investor Conference.
Bloomberg told investors that the company is due by 2025 $89 million in revenuerepresents 36% growth over the yearand submitted 88% gross margin for the year. Siri Bell’s commercial focus was seizure detection in acute care settings such as the ICU and emergency department, which Bloomberg described as close 2 billion dollars total market size. He added that the company has reached several milestones during 2025 aimed at expanding this opportunity, including the development of an algorithm for neonatal and pediatric patients and the first clearance related to the detection of delirium, which, according to him, has given Siri Bell a significant market boost. 3.5 billion dollars.
→ Uber and Jobi Aviation Team Up: Game Changer or Hype?
Blumberg cited SiriBell technology as a critical challenge in diagnosing non-convulsive disorders in acute care. Unlike epilepsy-related seizures, which are often seen, seizures are frequent in the ICU and ED settings. UnaffectedCan last for hours or days, and can be life-threatening. he said 92% Abnormalities in these patients are non-neurological, making EEG the only diagnostic method.
He emphasized the importance of timely diagnosis in cases of prolonged seizure activity, including “status epilepticus,” which he describes as a community-defined term for seizures lasting five minutes or more. Delays can worsen outcomes, and he noted that the effectiveness of first-line treatment decreases over time, citing a one-hour delay as reducing the material effect.
→ Wholesale Cost: Buy now, get paid later in cash and returns
Blumberg said that professional guidelines have increasingly recognized the need for rapid detection based on EEG, referring to the recommendations of the Neurocritical Care Society from 2012 that call for diagnosis within 15-60 minutes when status epilepticus is suspected, and similar recognition in 2020 by the American Heart Association and in 2022 by the American Stroke Association and 20221.
He argued that traditional EEG workflows are designed for outpatient epilepsy diagnosis and are not appropriate for urgent acute care needs because they require specialized technicians to set up and interpret neurologists—resources that may not be available at night or on weekends. Siri Bell’s approach, he said, reduces signal acquisition to approx five minutes and enables continuous monitoring.
→ Imperius stock price boosted by hyper growth outlook
The system uses a single patient disposable headband (and a newly introduced head cap for children) connected to a reusable recorder. Data is sent to the cloud via hospital Wi-Fi, allowing neurologists to remotely access the raw EEG. On top of that, the cerebellum to clarify The algorithm provides bedside seizure detection and alerts, translating complex EEG signals into an easy-to-interpret “seizure load” trend line that indicates how much time the patient spent in a seizure in the last five minutes.
Bloomberg said SiriBell recently received approval for use in patients under the age of 18, enabling the company to offer its seizure detection algorithm to pediatric patients. He said that the physical form factor was already there, but the algorithm was not. The company has also introduced a special head cap for children.
He explained it closely 400 million dollar market expansion Opportunity Cerebral is beginning to use pediatric and neonatal sites in its installed base and is preparing for a planned launch. Q2.
In newborns, he said, the need can be even more acute: seizures remain common and largely painless, clinicians can struggle to identify seizures empirically, and guidelines may recommend an EEG without direct clinical evidence when risk factors are present. One hour of arrest in this population can cause significant and potentially permanent neurological impairment, Blumberg said.
The Siri Bell business model includes two revenue streams:
Subscription income: a fixed monthly fee covering hardware access and software/AI; regarding to 25% Income level approx 97% gross marginAccording to Bloomberg.
Disposable headbands/head caps: typically used for one patient and then left between patients; regarding to 75% of revenue
Blumberg said that the model supports the ability to predict and clarified that the company has produced 31 consecutive quarters of continuous growth. Despite this move, he said that Siri Bell is just about 3% Enter the US foreclosure market. The company is currently installed in approx 647 hospitals Out of anticipation 6000 US hospitals with an ICU or emergency department. He also said that it is about logging into existing accounts 30%And these high users – when the size of the hospital is controlled – use about the product three times More than average users, which management sees as an opportunity for deep profit.
In terms of going to market, Bloomberg said the company has expanded its field manager coverage significantly 35 regions by 2024 you 55 by Q3 20252026 with those recruitments becoming profitable.
Blumberg framed SiriBell’s long-term vision in three horizons, starting with becoming the standard of care for seizure detection in acute care, then making “EEG a vital sign” by putting additional algorithms on the platform to help clinicians distinguish between conditions that exist in similarly altered patients.
He said the company received FDA approval for delirium November 2025 And provides additional payment submission of new technology, which may support the payment. He described delirium as an “acute failure of the brain”, affecting approx 3 million patients in the United States each yearapprox 30% In and around ICU patients 80% of mechanically ventilated patients. Blumberg said about one a day is in delirium in the ICU 10% increase in mortalityand that ICU delirium survivors are around 60% chance Development of dementia after discharge.
He said there is currently no validated diagnostic tool for delirium and described the CAM-ICU as the current standard—an assessment protocol that can be effective when used holistically but may be difficult to implement consistently in a chaotic ICU setting. Siri Bell is running a pilot of Delirium this year and expects a full launch Later this year or in Q1 next year.
For Stroke, Bloomberg said the company has received FDA breakthrough designations that have been announced January 2026which can provide a quick review and possible payment method. He noted that the company had to submit preliminary data on technical feasibility and that the FDA had set criteria for treating it as a new life-saving technology. He said Cerebral still plans to progress through clinical and regulatory pathways for stroke.
In a question-and-answer session, Blumberg addressed why adoption has not been high, pointing to the complexity of changing the long-established EEG workflow and focusing on cost to multiple hospital stakeholders, including ICU and ED physicians, nurses, neurologists, and hospital leadership. He described the sales cycle as long but said that once implemented, accounts require little maintenance and can be difficult for competitors to dislodge.
He said high-profit accounts typically have strong internal advocacy, efficient workflow design (including order sets), budget ownership close to bedside clinicians, and department-wide deployments. Bloomberg also said the company moved from positioning the product as an “overnight and weekend” solution at the beginning of the business to target wider use as a first-line tool.
Regarding competition, Bloomberg said Bell is a category creator and market leader, and has been an active competitor in the space for several years. He said the company is still winning business and not losing accounts, and argued that SiriBell’s algorithmic capabilities, data, and planned multi-platform approach help position it competitively.
Regarding operating profit and profitability, Bloomberg said that most of the sales infrastructure investment is geared towards growth, with field managers focusing on bringing accounts from initial engagement through launch and then delivering them. He said clinical account managers also focus largely on growth, including department expansion and protocol best practices, with minimal “babysitting” or case coverage. He added that the company had 159 million dollars in post-IPO capital and described the cash burn as “reasonable”, emphasizing the goal of maintaining flexibility without the need to raise additional capital.
CeriBell Corp (NASDAQ: CBLL ) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emission (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of hearing impairments in children. SiriBell solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through immediate intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to simplify testing workflows.
The article “CeriBell conference: CFO highlights 36% revenue growth, expands EEG platform to pediatrics and delirium” was originally published by MarketBeat.
